Evidence map›Paper›PMID 34489288›Full record

ArticleBMJ open2021

Relapse prevention group therapy via video-conferencing for substance use disorder: protocol for a multicentre randomised controlled trial in Indonesia.

Chika Yamada, Kristiana Siste, Enjeline Hanafi, Youdiil Ophinni, Evania Beatrice, Vania Rafelia, Peter Alison, Albert Limawan, Tomohiro Shinozaki, Toshihiko Matsumoto and 1 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Chika Yamada *Department of Environmental Coexistence, Center for Southeast Asian Studies, Kyoto University, Kyoto, Japan chika128@cseas.kyoto-u.ac.jp.ORCID 0000-0002-6288-5532
Kristiana Siste *Department of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.ORCID 0000-0001-7435-6243
Enjeline Hanafi *Department of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.ORCID 0000-0003-1668-3347
Youdiil Ophinni *Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.ORCID 0000-0001-9443-1538
Evania BeatriceDepartment of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Vania RafeliaDepartment of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Peter AlisonDepartment of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Albert LimawanDepartment of Psychiatry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Tomohiro ShinozakiDepartment of Information and Computer Technology, Faculty of Engineering, Tokyo University of Science, Tokyo, Japan.ORCID 0000-0003-3395-9691
Toshihiko MatsumotoDepartment of Drug Dependence Research, National Center of Neurology and Psychiatry, Tokyo, Japan.ORCID 0000-0002-7076-2161
Ryota SakamotoDepartment of Environmental Coexistence, Center for Southeast Asian Studies, Kyoto University, Kyoto, Japan.ORCID 0000-0002-0774-9925
University of Indonesia · IDKyoto University · JPNational Center of Neurology and Psychiatry · JPRagon Institute of MGH, MIT and Harvard · USTokyo University of Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSubstance use disorder (SUD) is a leading contributor to the global burden of disease. In Indonesia, the availability of formal treatment for SUD falls short of the targeted coverage. A standardised therapeutic option for SUD with potential for widespread implementation is required, yet evidence-based data in the country are scarce. In this study, we developed a cognitive behavioural therapy (CBT)-based group telemedicine model and will investigate effectiveness and implementability in a multicentre randomised controlled trial.

methodsA total of 220 participants will be recruited from the social networks of eight sites in Indonesia: three hospitals, two primary healthcare centres and three rehabilitation centres. The intervention arm will participate in a relapse prevention programme called the Indonesia Drug Addiction Relapse Prevention Programme (Indo-DARPP), a newly developed 12-week module based on CBT and motivational interviewing constructed in the Indonesian context. The programme will be delivered by a healthcare provider and a peer counsellor in a group therapy setting via video-conferencing, as a supplement to participants' usual treatments. The control arm will continue treatment as usual. The primary outcome will be the percentage increase in days of abstinence from the primarily used substance in the past 28 days. Secondary outcomes will include addiction severity, quality of life, motivation to change, psychiatric symptoms, cognitive function, coping, and internalised stigma. Assessments will be performed at baseline (week 0), post-treatment (week 13), and 3 and 12 months post-treatment completion (weeks 24 and 60). Retention, participant satisfaction, and cost-effectiveness will be assessed as the implementation outcomes. ETHICS AND DISSEMINATION: The study protocol was reviewed and approved by the Ethics Committees of Universitas Indonesia and Kyoto University. The results will be disseminated via academic journals and international conferences. Depending on trial outcomes, the treatment programme will be advocated for adoption as a formal healthcare-based approach for SUD. TRIAL REGISTRATION NUMBER: UMIN000042186.

Indexed as

Psychotherapy, GroupSubstance-Related DisordersCost-Benefit AnalysisHumansIndonesiaMulticenter Studies as TopicQuality of LifeRandomized Controlled Trials as TopicSecondary Preventionclinical trialspsychiatrysubstance misusetelemedicine

Identifiers

PMID34489288
PMCPMC8422497
OpenAlexW3196902085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.